Candesartan, an AT1R inhibitor, was reported to decrease RGC loss in experimental rat glaucoma with oral dosing [25], no detailed studies were performed in that report to show the mechanism by which the drug acted. This evidence concerns the gene AGTR1 and glaucoma.